T1	Participants 173 277	elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
T2	Participants 452 516	elderly patients with advanced, low-grade non-Hodgkin's lymphoma
T3	Participants 675 779	One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response.